MG vs REPL Comparison

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.